NEW YORK , June 20, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB).Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=86310&from=4CLASS PERIOD: February 3, 2022 to February 13, 2 ...

LOS ANGELES, June 19, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biogen Inc. (“Biogen” or “the Company”) (NASDAQ: BIIB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s securities between February 3, 2022 and February 13, 2024, inclusive (the “Class Period”), ...

The Alzheimer's treatment landscape presents a compelling opportunity for investors in healthcare and biotech. Alzheimer's disease is a progressive and debilitating neurodegenerative disorder that poses a significant and growing threat to global health and economic well-being. With an estimated 6.7 million Americans currently living with Alzheimer's and projected costs exceeding $2 trillion over the next decade, the urgency for effective treatments is undeniable. This unmet medical need has created an arena ...

NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB). Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=85786&from=3 CLASS PERIOD: February 3, 2022 to Februar ...

RADNOR, Pa., June 17, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc. ("Biogen") (NASDAQ: BIIB). The action charges Biogen with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects.  As a result of Biogen's mat ...

NEW YORK, June 17, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB).Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=85496&from=4CLASS PERIOD: February 3, 2022 to February 13, 20 ...

The healthcare sector will be one area of secular growth over the next decade. Several demand drivers will benefit the best healthcare stocks to buy across the entire value chain.First, let’s highlight the major healthcare tailwinds starting with an aging population. The baby boomer generation (20% of the U.S. population) is transitioning into older age. This shift will create a surging demand for healthcare services and products such as insurance, pharmaceuticals, medical devices and hospitals.Indeed, esti ...

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Colorado on behalf of those who acquired Biogen, Inc (“Biogen” or the “Company”) (NASDAQ: BIIB) securities during the period of February 3, 2022 through February 13, 2024, inclusive (“the Class Period”). Investors have until July 22, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. [Click here t ...

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq: BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/biogen-inc-investigation. Why is Biogen being Sued? On May 22, 2024, Biogen was sued for violations of the federal securities laws. The complaint alleges that between February 3, 2022 and F ...

文章核心观点 - 公司正在经历从衰退到增长的转型,通过重新调整组织架构、优化资本配置等措施来提升财务纪律和长期收益 [3][4][5][6] - 公司主要产品LEQEMBI的上市推广正在加速,通过扩大销售团队、开展DTC营销等措施来推动患者数量增长 [26][27][34][35][36][37] - 公司新药SKYCLARYS在罕见病领域表现良好,正在积极拓展覆盖面,并期待通过扩大适应症来带来进一步增长 [48][49][50][60] - 公司与Sage合作的新药ZURZUVAE在产科医生群体中表现超预期,未来有望进一步提升市场份额 [66][67][68][69][70][71][72] - 公司正在通过优化资本配置、提升运营效率等措施来改善利润率,并保持积极的并购态度以推动长期增长 [74][75][76][77][78][79] 根据目录分组总结 LEQEMBI上市推广 - 公司正在通过扩大销售团队、开展DTC营销等措施来推动LEQEMBI的患者数量增长 [26][27][34][35][36][37] - 公司正在积极推进LEQEMBI的剂型扩展,包括静脉维持剂型和皮下注射剂型,以为患者提供更多选择 [39][40][41][42][43] - 公司对LEQEMBI在Medicare Part D改革下的定价和覆盖情况保持谨慎态度,将密切关注相关政策变化 [44][45][46][47] SKYCLARYS在罕见病领域的表现 - 公司在罕见病领域积累了丰富经验,SKYCLARYS在弗里德里希共济失调治疗领域表现良好 [48][49][50] - 公司正在积极拓展SKYCLARYS的覆盖面,包括通过AI模型发现更多潜在患者 [51][52][53] - 公司期待通过扩大适应症至儿童群体来带来进一步增长机会 [60] ZURZUVAE在产科领域的表现 - 公司与Sage合作推广ZURZUVAE,在产科医生群体中表现超预期 [65][66][67][68] - 公司正在积极应对产科医生在使用专科药房、事先授权等方面的教育需求 [71][72] - 公司对ZURZUVAE未来的增长前景保持乐观 [69][70] 公司整体经营情况 - 公司正在通过优化资本配置、提升运营效率等措施来改善利润率 [74][75][76] - 公司保持积极的并购态度,将继续寻求外部机会以推动长期增长 [77][78][79]